Clinical Trials

Pharmalot

Pharmalittle: Trump to require drug prices in ads; Europe cracks down on valsartan ingredients maker

By Ed Silverman

Futuristic medicine

First Opinion

How one pharmaceutical company is reinventing the clinical trial

By Andreas Koester

advertisement

Locked file cabinet

First Opinion

All study participants have a right to know their own results. My lab has been doing that for years

By Julia G. Brody

advertisement

Doctor using digital tablet

First Opinion

Digital technologies hold the key to streamlining and improving clinical trials

By Jake LaPorte

A doctor treats a patient at Wang Fu Hospital in Beijing.

First Opinion

China isn’t yet ready to conduct clinical trials for the pharma industry

By Anne Poli

Lessons Learned

Lessons Learned

Lessons Learned: This is how you take a public health degree to a startup and back to academia

By Megha Satyanarayana

Patient Advocacy Funding

Pharmalot

Millions in fines are adding up as clinical trial information goes unreported

By Ed Silverman

advertisement

Kopy Katz

Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

advertisement

Acne

Biotech

Dermira discontinues development of acne drug after two late-stage trials fail

By Adam Feuerstein

neurological cognitive tests - Alzheimers

First Opinion

FDA’s updated standards remove an unnecessary barrier to testing Alzheimer’s drugs

By Howard M. Fillit

Jonathan Kimmelman

In the Lab

How well can you predict the outcome of clinical trials? Not as well as you may think

By Andrew Joseph

Medical syringe

Health

Unregulated herpes experiments expose ‘black hole’ of accountability

By Marisa Taylor — Kaiser Health News

Treadmill

First Opinion

Why did it take the CDC so long to reverse course on debunked treatments for chronic fatigue syndrome?

By Julie Rehmeyer and David Tuller

Streptococcus pneumoniae bacteria

Biotech

Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

By Adam Feuerstein

John Maraganore

Business

Stakes are high as Alnylam awaits results from novel rare disease therapy

By Adam Feuerstein

Neurons

Business

5 things to know about Sage’s must-win drug trials in postpartum depression

By Adam Feuerstein

Tapeworm Cancer ChestXRay

Pharma

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

By Adam Feuerstein

Neurons

Biotech

7 things to know about Sage Therapeutics’ pivotal trial of a drug for severe epilepsy

By Adam Feuerstein

Chemo Drip

Biotech

Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions

By Adam Feuerstein

Cancer Care Costs

First Opinion

How do we solve the crisis in cancer communication?

By Lynn O'Connor Vos

Jesi Stracham

Health

Experimental scaffold hasn’t reversed her paralysis, but she’s embraced life ‘with wheels as legs’

By Rebecca Robbins

Cancer treatment

Gut Check

Do cancer clinical trials exaggerate the real-world benefits of drugs?

By Sharon Begley

Hepatitis Drugs

Pharmalot

How much longer will Gilead wait before buying its way out of the doldrums?

By Ed Silverman

Colontown

Health

‘Colontown’ gives cancer patients an edge in finding new treatments

By David Steen Martin

Right-to-Try Laws

First Opinion

Right-to-try laws could curtail the development of innovative new therapies

By Alison Bateman-House

Compassionate use panel illustration

Business

Novel system to get dying patients an experimental cancer drug raises hopes — and thorny questions

By Karen Weintraub

Sanofi

Pharmalot

What clinical trial results? Now you can see who isn’t sharing their findings

By Ed Silverman

Data Sharing

First Opinion

In defense of data sharing, but done in the right way

By Jeffrey M. Drazen and Isaac S. Kohane

Broken leg

In the Lab

Major trial casts doubt on leading device to heal bone fractures

By Charles Piller